# ACRS catalysts: Aclaris Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/acrs/catalysts

> Aclaris Therapeutics, Inc. (ACRS) has 4 upcoming catalysts. The next is the ATI-052 trial start, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ACRS?

Aclaris Therapeutics, Inc. (ACRS) has 4 upcoming catalysts. The next is the ATI-052 trial start, Q1 2027. SEC Form 8-K: "The Registrant intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/companies/acrs/catalysts)

Source: SEC Form 8-K, accession 0001104659-26-127478, https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-20261116x8k.htm (retrieved 2026-11-16). Last confirmed 2026-11-16. Cite: https://sec-api.dev/companies/acrs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Aclaris Therapeutics, Inc. |
| Ticker | ACRS (Nasdaq) |
| SEC CIK | 1557746 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/acrs |

## Cash runway

Cash $204.6M as of 2026-09-30; quarterly burn $24.1M; about 25.5 months of runway at that rate (XBRL company facts, accession 0001104659-26-123374).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 14, 2017 | [Eskata (hydrogen peroxide) FDA approval](https://sec-api.dev/pdufa/hydrogen-peroxide) | ACRS |  | completed, approved | "NDA209305 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20171214, review_priority STANDARD; sponsor_name ACLARIS; product ESKATA (HYDROGEN PEROXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209305%22)) |
| Jan 2024 | [Lepzacitinib topline data readout](https://sec-api.dev/pdufa/lepzacitinib) | ACRS | mild to severe atopic dermatitis | completed, positive | "In January 2024, we announced positive top-line results from our Phase 2b multicenter, randomized, double-blind, vehicle-controlled, parallel-group trial of lepzacitinib in patients with mild to severe atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1557746/000155837025010789/acrs-20250630x10q.htm)) |
| Q1 2025 | [ATI-052 trial start](https://sec-api.dev/pdufa/ati-052) | ACRS |  | scheduled | "Announced Plan to File an Investigational New Drug (IND) Application for ATI-052 in the First Quarter of 2025: Following allowance of the IND, Aclaris expects to initiate a Phase 1 clinical trial evaluating single ascending doses and multiple ascending doses of ATI-052." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/acrs-20250227xex99d1.htm)) |
| February 27, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025001679/acrs-20250227xex99d1.htm)) |
| Q2 2025 | [Bosakitug trial start](https://sec-api.dev/pdufa/bosakitug) | ACRS | moderate to severe atopic dermatitis | scheduled | "Aclaris Expects to Initiate Enrollment in Placebo-Controlled Two-Arm Phase 2 Trial in Atopic Dermatitis (AD) in the Second Quarter of 2025: Based on the potency of bosakitug observed in preclinical and clinical studies to date, including the compelling results of the Phase 2a single arm trial in AD, Aclaris intends to initiate a two-arm placebo-controlled Phase 2 trial of bosakitug in approximately 90 patients with moderate-" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508xex99d1.htm)) |
| May 8, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508xex99d1.htm)) |
| Jun 2025 | [Bosakitug trial start](https://sec-api.dev/pdufa/bosakitug) | ACRS |  | completed | "In June 2025, we initiated a Phase 2 trial to evaluate the efficacy, safety, tolerability, pharmacokinetics ("PK") and pharmacodynamics ("PD") of bosakitug compared to placebo in 109 patients with moderate to severe atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1557746/000110465926123374/acrs-20260930x10q.htm)) |
| Jun 2025 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS |  | scheduled | "The Company expects to report top line results in June 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025006851/acrs-20250508xex99d1.htm)) |
| July 29, 2025 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS | moderate-to-severe AD | completed, positive | "WAYNE, Pa., July 29, 2025 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive top-line results from its open-label, single-arm Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), in 14 patients with moderate-to-severe atopic dermatitis (AD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025009739/acrs-20250729xex99d2.htm)) |
| August 7, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/acrs-20250807xex99d1.htm)) |
| November 6, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106xex99d1.htm)) |
| Q1 2026 | [ATI-052 trial start](https://sec-api.dev/pdufa/ati-052) | ACRS |  | scheduled | "- Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106xex99d1.htm)) |
| 1H 2026 | [Modzatinib trial start](https://sec-api.dev/pdufa/modzatinib) | ACRS |  | scheduled | "The Company intends to initiate a Phase 2 trial in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465925107353/acrs-20251106xex99d1.htm)) |
| January 6, 2026 | [ATI-052 interim data readout](https://sec-api.dev/pdufa/ati-052) | ACRS |  | completed, positive | "WAYNE, Pa., January 6, 2026 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive interim results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106xex99d1.htm)) |
| February 26, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226xex99d1.htm)) |
| February 26, 2026 | [ATI-052 trial start](https://sec-api.dev/pdufa/ati-052) | ACRS |  | completed | "Announced Initiation of Two Phase 1b Proof-of-Concept (POC) Trials of ATI-052: Following positive interim Phase 1a SAD/MAD results, the Company has initiated Phase 1b POC studies in AD and asthma." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926020070/acrs-20260226xex99d1.htm)) |
| Apr 2026 | [ATI-052 topline data readout](https://sec-api.dev/pdufa/ati-052) | ACRS |  | completed, positive | "In April 2026, we announced positive full top-line results from our Phase 1a single ascending dose ("SAD") and multiple ascending dose ("MAD") portion of our first-in-human study evaluating ATI-052 in healthy volunteers." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1557746/000110465926123374/acrs-20260930x10q.htm)) |
| Q2 2026 | [ATI-052 topline data readout](https://sec-api.dev/pdufa/ati-052) | ACRS |  | scheduled | "We expect to announce complete top-line results from the SAD and MAD cohorts in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1557746/000110465926020540/acrs-20251231x10k.htm)) |
| May 7, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507xex99d1.htm)) |
| 2H 2026 | [ATI-052 topline data readout](https://sec-api.dev/pdufa/ati-052) | ACRS | atopic dermatitis | scheduled | "Dosing is ongoing in both trials, and top line results from both are expected in the second half of 2026. (press releases here and here)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507xex99d1.htm)) |
| 2H 2026 | [Aclaris Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | scheduled | "- Enrollment and Dosing Ongoing in Phase 1b Trials in Asthma and Atopic Dermatitis (AD) with Top Line Results Expected in the Second Half of 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/acrs-20260428xex99d2.htm)) |
| 2H 2026 | [Aclaris Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | scheduled | "Enrollment is ongoing in both trials, and top line results from both are expected in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/acrs-20260428xex99d2.htm)) |
| August 6, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806xex99d1.htm)) |
| September 21, 2026 | [ATI-045 primary completion](https://sec-api.dev/pdufa/ati-045) | ACRS | Atopic Dermatitis; Atopic; Dermatitis | completed | "NCT07011706 (ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor Aclaris Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011706)) |
| Sep to Dec 2026 | [ATI-045 topline data readout](https://sec-api.dev/pdufa/ati-045) | ACRS | Atopic Dermatitis; Atopic; Dermatitis | scheduled | "NCT07011706 (ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-21 (ACTUAL); Lead Sponsor Aclaris Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07011706)) |
| Q4 2026 | [Bosakitug topline data readout](https://sec-api.dev/pdufa/bosakitug) | ACRS |  | scheduled | "The Company expects to provide top line results in the fourth quarter of 2026. (press release here)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926056669/acrs-20260507xex99d1.htm)) |
| Q4 2026 | [Modzatinib trial start](https://sec-api.dev/pdufa/modzatinib) | ACRS |  | scheduled | "- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926123039/acrs-ex99d1.htm)) |
| November 5, 2026 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926123039/acrs-ex99d1.htm)) |
| Q1 2027 | [ATI-052 trial start](https://sec-api.dev/pdufa/ati-052) | ACRS |  | scheduled | "The Registrant intends to initiate a Phase 2b trial of ATI-052, its anti-TSLP/IL-4Rα bispecific antibody, in eosinophilic esophagitis in the first quarter of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-20261116x8k.htm)) |
| 2H 2027 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS |  | scheduled | "Modzatinib: Top line results from the OLP cohort are expected in the second half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-ex99d2.htm)) |
| March 2029 | [Modzatinib primary completion](https://sec-api.dev/pdufa/modzatinib) | ACRS | Lichen Planus | scheduled | "NCT07935590 (Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Aclaris Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935590)) |
| Mar to Jun 2029 | [Modzatinib topline data readout](https://sec-api.dev/pdufa/modzatinib) | ACRS | Lichen Planus | scheduled | "NCT07935590 (Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Aclaris Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07935590)) |

## Drugs

- [ATI-045](https://sec-api.dev/pdufa/ati-045): Atopic Dermatitis
- [ATI-052](https://sec-api.dev/pdufa/ati-052): atopic dermatitis
- [Bosakitug](https://sec-api.dev/pdufa/bosakitug): moderate to severe atopic dermatitis
- [Eskata (hydrogen peroxide)](https://sec-api.dev/pdufa/hydrogen-peroxide): 
- [Lepzacitinib](https://sec-api.dev/pdufa/lepzacitinib): mild to severe atopic dermatitis
- [Modzatinib](https://sec-api.dev/pdufa/modzatinib): moderate to severe atopic dermatitis, moderate-to-severe ad, Lichen Planus

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/acrs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ACRS catalysts: Aclaris Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/acrs/catalysts

```bibtex
@misc{secapidev_companies_acrs_catalysts_20261116,
  title        = {ACRS catalysts: Aclaris Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/acrs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_acrs_catalysts_20261116","title":"ACRS catalysts: Aclaris Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/acrs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
